Compositions and methods for modulating ghrelin-mediated conditions
In certain aspects, the preproghrelin gene, but not the ghrelin receptor (GHS-R1a) is required for normal integration of thermoregulation and sleep in mice. Particular aspects provide methods for modulation of thermoregulation and other ghrelin-mediated conditions (e.g., reduction of appetite or food intake, reduction of body weight or treatment of obesity, reduction of body temperature or induction of hypothermia, etc.), comprising administration of an inhibitor of ghrelin expression, and including, e.g., siRNA inhibition for treatment of obesity and for modulation of thermoregulation (e.g., induction of hypothermia in surgical settings benefiting from same). Additionally provided are methods for reducing body temperature or induction of hypothermia, comprising administration to a mammalian subject in need thereof an amount of an anti-obestatin antibody agent sufficient to reduce body temperature or induce hypothermia. Further methods comprise administration of a ghrelin peptide antagonist.
1. A method for suppressing food intake or appetite, comprising:
administration to a mammalian subject in need thereof an amount of ghrelin or preproghrelin siRNA agent sufficient to suppress ghrelin or preproghrelin mRNA, wherein the ghrelin or preproghrelin siRNA agent, comprises a nucleic acid sequence of at least 19 contiguous nucleotides identical or complementary to the preproghrelin mRNA sequence encoding the first 5 amino acids (Phe-Asn-Ala-Pro-Phe) (SEQ ID NO:18) of obestatin, and wherein suppression of food intake or appetite is afforded.
2. A method for reducing body weight or treating obesity, comprising:
administration to a mammalian subject in need thereof an amount of ghrelin or preproghrelin siRNA agent sufficient to suppress ghrelin or preproghrelin mRNA, wherein, the ghrelin or preproghrelin siRNA agent comprises a nucleic acid sequence of at least 19 contiguous nucleotides identical or complementary to the preproghrelin mRNA sequence encoding the first 5 amino acids (Phe-Asn-Ala-Pro-Phe)(SEQ ID NO: 18) of obestatin, and wherein reduction of body weight or treating obesity is afforded.
3. The method of any one of claims 1 through 2 , wherein the ghrelin or preproghrelin siRNA agent, comprises a sequence complementary to a target sequence selected from SEQ ID NOS:1-5, complements thereof, and contiguous portions thereof.
4. The method of claim 3 , wherein the siRNA agent comprises overhanging ends, which may or may not be complementary to the target sequence.
5. The method of any one of claims 1 through 2 , wherein administration comprises oral delivery.
6. The method of claims 1 through 2 , wherein the suppression of ghrelin or preproghrelin mRNA is transient or reversible.
7. A method for reducing body temperature or induction of hypothermia, comprising:
administration to a mammalian subject in need thereof an amount of obestatin siRNA agent sufficient to suppress obestatin mRNA, wherein the obestatin siRNA agent, comprises a nucleic acid sequence of at least 19 contiguous nucleotides identical or complementary to the preproghrelin mRNA sequence encoding the first 5 amino acids (Phe-Asn-Ala-Pro-Phe) (SEQ ID NO:18) of obestatin, and wherein reducing body temperature or induction of hypothermia is afforded.
8. The method of claim 7 , wherein the obestatin siRNA agent, comprises a sequence complementary to a target sequence selected from SEQ ID NOS:1-5, complements thereof, and contiguous portions thereof.
9. The method of claim 8 , wherein the siRNA agent comprises overhanging ends, which may or may not be complementary to the target sequence.
10. The method of claim 7 , wherein administration comprises oral delivery.
11. The method of claim 7 , wherein suppression of obestatin mRNA is transient or reversible.
12. The method of claim 7 , wherein reducing body temperature or induction of hypothermia comprises regulating at least one of surgical hypothermia, trauma-related hypothermia, and cardiac-related hypothermia.